Acta Scientific Microbiology (ASMI) (ISSN: 2581-3226)

Research Article Volume 3 Issue 4

COVID-19 Treatment-Review of All Published Literatures till Date

Rajib Dutta*

MD Neurology, India

*Corresponding Author: Rajib Dutta, MD Neurology, India.

Received: March 25, 2020; Published: April 01, 2020



 The outbreak of SARS-COV-2 (severe acute respiratory syndrome coronavirus 2), that began in December 2019, is still spreading worldwide and presents a significant and urgent threat to global health and economy. Patients with COVID-19 are at risk of acute respiratory distress syndrome (ARDS), respiratory failure and death. Patients aged > 60 years with comorbidities, children and health care workers are highly vulnerable to this virus. The tissue receptor for COVID-19 is Angiotensin-converting enzyme 2 (ACE2) and higher levels of ACE2 can protect against ARDS. Scientists all over the world are actively working to explore drugs or antivirals specific to the virus. Several agents has been reported to be effective, however trials are on currently. Here in this review all therapeutic agents against COVID-19 reported in recent times after the outbreak are being discussed.

Keywords: SARS-COV-2; COVID-19; Treatment



  1. COVID-19 Coronavirus Pandemic.
  2. Gao J., et al. “Breakthrough: Chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies”. BioScience Trends 1 (2020): 72-73.
  3. Audio transcript of the news briefing held by the State Council of China on February 17, 2020. The National Health Commission of the People's Republic of China (2020).
  4. Wang M., et al. “Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) In vitro”. Cell Research 3 (2020): 269-271.
  5. Chinese Clinical Trial Registry.
  6. Warren TK., et al. “Therapeutic efficacy of the small molecule GS-5734 against Ebola virus in rhesus monkeys”. Nature7594 (2016): 381-385.
  7. Sheahan TP., et al. “Broad-spectrum antiviral GS-5734 inhibits both epidemic and zoonotic coronaviruses”. Science Translational Medicine 396 (2017): eaal3653.
  8. Agostini ML., et al. “Coronavirus Susceptibility to the Antiviral Remdesivir (GS-5734) Is Mediated by the Viral Polymerase and the Proofreading Exoribonuclease”. mBio 2 (2018): e00221-E002218.
  9. Lo MK., et al. “GS-5734 and its parent nucleoside analog inhibit Filo-, Pneumo-, and Paramyxoviruses”. Scientific Reports 7 (2017): 43395.
  10. Remdesivir could be promising drug candidate to treat coronavirus. Coronavirus daily update (2020).
  11. Brunk D. "Remdesivir Under Study as Treatment for Novel Coronavirus". Medscape (2020).
  12. Holshue ML., et al. “First Case of 2019 Novel Coronavirus in the United States”. The New England Journal of Medicine 10 (2020): 929-936.
  13. Harmon A. "Inside the Race to Contain America's First Coronavirus Case". The New York Times (2020).
  14. Johnson CY. "Scientists Hope an Antiviral Drug Being Tested in China Could Help Patients". The Washington Post (2020).
  15. Taylor NP. "Gilead mulls repositioning failed Ebola drug in China virus". Fierce Biotech (2020).
  16. Joseph SS and Samuel M. "Gilead working with China to test Ebola drug as new coronavirus treatment". Thomson Reuters (2020).
  18. Coronavirus: a Genova c'è primo guarito con Remdesivir (2020).
  19. Zhao Y. "Three drugs fairly effective on novel coronavirus at cellular level". China News Service (2020).
  20. Lim J., et al. “Case of the Index Patient Who Caused Tertiary Transmission of COVID-19 Infection in Korea: the Application of Lopinavir/Ritonavir for the Treatment of COVID-19 Infected Pneumonia Monitored by Quantitative RT-PCR”. Journal of Korean Medical Science 6 (2020): e79.
  21. Touret F and de Lamballerie X. “Of chloroquine and COVID-19”. Antiviral Research 177 (2020): 104762.
  22. “Guidelines for the Prevention, Diagnosis, and Treatment of Novel Coronavirus-induced Pneumonia”. The 5th edition (2020).
  23. “Guidelines for the Prevention, Diagnosis, and Treatment of Novel Coronavirus-induced Pneumonia”. The 6th edition (2020).
  24. Shanghai Institute of Materia Medica website, Chinese Academy of Sciences. A joint research team of the Shanghai Institute of Materia Medica and Shanghai Tech University discover a group of old and traditional Chinese medicines that may be efficacious in treating the novel form of pneumonia (2020).
  25. News (2020).
  26. Cao B., et al. “A Trial of Lopinavir-Ritonavir in Adults Hospitalized with Severe Covid-19 [published online ahead of print”. The New England Journal of Medicine (2020): 10.
  27. Baron SA., et al. “Teicoplanin: an alternative drug for the treatment of coronavirus COVID-19? [published online ahead of print”. The International Journal of Antimicrobial Agents (2020): 105944.
  28. Liu F., et al. “Patients of COVID-19 may benefit from sustained lopinavir-combined regimen and the increase of eosinophil may predict the outcome of COVID-19 progression [published online ahead of print”. International Journal of Infectious Diseases (2020): 30132-30136.
  29. Cortegiani A., et al. “A systematic review on the efficacy and safety of chloroquine for the treatment of COVID-19”. The Journal of Critical Care 20 (2020): 30390-30397.
  30. Deng L., et al. “Arbidol combined with LPV/r versus LPV/r alone against Corona Virus Disease 2019: a retrospective cohort study [published online ahead of print”. Journal of Infection 20 (2020): 30113-30114.
  31. Devaux CA., et al. “New insights on the antiviral effects of chloroquine against coronavirus: what to expect for COVID-19?” The International Journal of Antimicrobial Agents (2020): 105938.
  32. Sun ML., et al. “Inhibitors of RAS Might Be a Good Choice for the Therapy of COVID-19 Pneumonia”. Zhonghua Jie He He Hu Xi Za Zhi 3 (2020): 219-222.
  33. Multicenter collaboration group of Department of Science and Technology of Guangdong Province and Health Commission of Guangdong Province for chloroquine in the treatment of novel coronavirus pneumonia. “Expert consensus on chloroquine phosphate for the treatment of novel coronavirus pneumonia”. Zhonghua Jie He He Hu Xi Za Zhi3 (2020): 185-188.
  34. Du B., et al. “Pharmacotherapeutics for the new coronavirus pneumonia”. Zhonghua Jie He He Hu Xi Za Zhi3 (2020): 173-176.
  35. Li H., et al. “Potential antiviral therapeutics for 2019 Novel Coronavirus”. Zhonghua Jie He He Hu Xi Za Zhi3 (2020): 170-172.
  36. Chen Q., et al. “A report of clinical diagnosis and treatment of nine cases of coronavirus disease 2019”. Journal of Medical Virology (2020).
  37. Chenoweth AM., et al. “Harnessing the immune system via FcγR function in immune therapy: A pathway to next-gen mAbs”. Immunology and Cell Biology (2020).
  38. Yao X., et al. “In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)”. Clinical Infectious Diseases (2020): 237.
  39. Zhou D., et al. “COVID-19: a recommendation to examine the effect of hydroxychloroquine in preventing infection and progression”. Journal of Antimicrobial Chemotherapy (2020): 114.
  40. Chen YW., et al. “Prediction of the SARS-CoV-2 (2019-nCoV) 3C-like protease (3CL pro) structure: virtual screening reveals velpatasvir, ledipasvir, and other drug repurposing candidates”. F1000Research 9 (2020): 129.
  41. Zhu L., et al. “Successful recovery of COVID-19 pneumonia in a renal transplant recipient with long-term immunosuppression”. American Journal of Transplantation (2020).
  42. Batlle D., et al. “Soluble angiotensin-converting enzyme 2: a potential approach for coronavirus infection therapy?” Clinical Science 5 (2020): 543-545.
  43. Fan HH., et al. “Repurposing of clinically approved drugs for treatment of coronavirus disease 2019 in a 2019-novel coronavirus (2019-nCoV) related coronavirus model Chin”. Medical Journal (2020): 10.1097.
  44. Ren JL., et al. “Traditional Chinese medicine for COVID-19 treatment”. Pharmacological Research 155 (2020): 104743.
  45. Hoffmann M., et al. “SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor”. Cell 8674 (2020): 30229-30224.
  46. Zhou W., et al. “Potential benefits of precise corticosteroids therapy for severe 2019-nCoV pneumonia”. Signal Transduction and Targeted Therapy 5 (2020): 18.
  47. Gurwitz D. “Angiotensin receptor blockers as tentative SARS-CoV-2 therapeutics”. Drug Development and Research (2020).
  48. Fu Y., et al. “Understanding SARS-CoV-2-Mediated Inflammatory Responses: From Mechanisms to Potential Therapeutic Tools”. Virologica Sinica (2020).
  49. Xu J., et al. “Broad Spectrum Antiviral Agent Niclosamide and Its Therapeutic Potential”. ACS Infectious Diseases (2020).
  50. Chen L., et al. “Convalescent plasma as a potential therapy for COVID-19”. The Lancet Infectious Diseases 20 (2020): 30141-30149.
  51. Richardson P., et al. “Baricitinib as potential treatment for 2019-nCoV acute respiratory disease”. Lancet 10223 (2020): e30-e31.
  52. Dong L., et al. “Discovering drugs to treat coronavirus disease 2019 (COVID-19)”. Drug Discoveries and Therapeutics 1 (2020): 58-60.
  53. Information for Clinicians on Therapeutic Options for COVID-19 Patients.
  54. Gilead launches remdesivir’s Phase III trials in Covid-19 patients.
  55. Q Cai., et al. “Experimental Treatment with Favipiravir for COVID-19: An Open-Label Control Study”. Engineering (2020).
  56. Zhang J., et al. “Teicoplanin potently blocks the cell entry of 2019-nCoV”. Bio Rxiv (2020).


Citation: Rajib Dutta. “COVID-19 Treatment-Review of All Published Literatures till Date". Acta Scientific Microbiology 3.4 (2020): 215-219.


Acceptance rate30%
Acceptance to publication20-30 days

Indexed In

News and Events

  • Certification for Review
    Acta Scientific certifies the Editors/reviewers for their review done towards the assigned articles of the respective journals.
  • Submission Timeline for Upcoming Issue
    The last date for submission of articles for regular Issues is June 25, 2024.
  • Publication Certificate
    Authors will be issued a "Publication Certificate" as a mark of appreciation for publishing their work.
  • Best Article of the Issue
    The Editors will elect one Best Article after each issue release. The authors of this article will be provided with a certificate of "Best Article of the Issue"
  • Welcoming Article Submission
    Acta Scientific delightfully welcomes active researchers for submission of articles towards the upcoming issue of respective journals.

Contact US